Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

Myeloid zinc finger-1 regulates expression of cancer-associated fibroblast and cancer stemness profiles in breast cancer.

Kuo MC, Kuo PC, Mi Z.

Surgery. 2019 Jul 10. pii: S0039-6060(19)30322-8. doi: 10.1016/j.surg.2019.05.042. [Epub ahead of print]

PMID:
31301870
2.

Cancer stemness in bone marrow micrometastases of human breast cancer.

Kuo MC, Kothari AN, Kuo PC, Mi Z.

Surgery. 2018 Feb;163(2):330-335. doi: 10.1016/j.surg.2017.07.027. Epub 2017 Oct 5.

PMID:
28988933
3.

S-Nitrosylation of heterogeneous nuclear ribonucleoprotein A/B regulates osteopontin transcription in endotoxin-stimulated murine macrophages.

Gao C, Guo H, Wei J, Mi Z, Wai P, Kuo PC.

J Biol Chem. 2017 Feb 24;292(8):3542. doi: 10.1074/jbc.A117.313385. No abstract available.

4.

Characterization of short range DNA looping in endotoxin-mediated transcription of the murine inducible nitric-oxide synthase (iNOS) gene.

Guo H, Mi Z, Kuo PC.

J Biol Chem. 2017 Jan 20;292(3):1144. doi: 10.1074/jbc.A116.804062. No abstract available.

5.

Osteopontin and protein kinase C regulate PDLIM2 activation and STAT1 ubiquitination in LPS-treated murine macrophages.

Guo H, Mi Z, Bowles DE, Bhattacharya SD, Kuo PC.

J Biol Chem. 2017 Jan 20;292(3):1142. doi: 10.1074/jbc.A110.161869. No abstract available.

6.

Pancreatic Cancer and Osteopontin: The Relationship Remains Unclear.

Weber CE, Erşahin ÇH, Kuo PC, Mi Z.

Pancreas. 2016 Aug;45(7):e35-6. doi: 10.1097/MPA.0000000000000639. No abstract available.

PMID:
27400159
7.

Osteopontin-A Master Regulator of Epithelial-Mesenchymal Transition.

Kothari AN, Arffa ML, Chang V, Blackwell RH, Syn WK, Zhang J, Mi Z, Kuo PC.

J Clin Med. 2016 Mar 23;5(4). pii: E39. doi: 10.3390/jcm5040039. Review.

8.

Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis.

Coombes JD, Choi SS, Swiderska-Syn M, Manka P, Reid DT, Palma E, Briones-Orta MA, Xie G, Younis R, Kitamura N, Della Peruta M, Bitencourt S, Dollé L, Oo YH, Mi Z, Kuo PC, Williams R, Chokshi S, Canbay A, Claridge LC, Eksteen B, Diehl AM, Syn WK.

Biochim Biophys Acta. 2016 Jan;1862(1):135-44. doi: 10.1016/j.bbadis.2015.10.028. Epub 2015 Oct 31.

9.

Components of Hospital Perioperative Infrastructure Can Overcome the Weekend Effect in Urgent General Surgery Procedures.

Kothari AN, Zapf MA, Blackwell RH, Markossian T, Chang V, Mi Z, Gupta GN, Kuo PC.

Ann Surg. 2015 Oct;262(4):683-91. doi: 10.1097/SLA.0000000000001436.

10.

Green tea component epigallocatechin-3-gallate decreases expression of osteopontin via a decrease in mRNA half-life in cell lines of metastatic hepatocellular carcinoma.

Zapf MA, Kothari AN, Weber CE, Arffa ML, Wai PY, Driver J, Gupta GN, Kuo PC, Mi Z.

Surgery. 2015 Oct;158(4):1039-47; discussion 1047-8. doi: 10.1016/j.surg.2015.06.011. Epub 2015 Jul 17.

11.

Alcohol inhibits osteopontin-dependent transforming growth factor-β1 expression in human mesenchymal stem cells.

Driver J, Weber CE, Callaci JJ, Kothari AN, Zapf MA, Roper PM, Borys D, Franzen CA, Gupta GN, Wai PY, Zhang J, Denning MF, Kuo PC, Mi Z.

J Biol Chem. 2015 Apr 17;290(16):9959-73. doi: 10.1074/jbc.M114.616888. Epub 2015 Feb 24.

12.

Novel clinical therapeutics targeting the epithelial to mesenchymal transition.

Kothari AN, Mi Z, Zapf M, Kuo PC.

Clin Transl Med. 2014 Oct 15;3:35. doi: 10.1186/s40169-014-0035-0. eCollection 2014. Review.

13.

Osteopontin is up-regulated in chronic hepatitis C and is associated with cellular permissiveness for hepatitis C virus replication.

Choi SS, Claridge LC, Jhaveri R, Swiderska-Syn M, Clark P, Suzuki A, Pereira TA, Mi Z, Kuo PC, Guy CD, Pereira FE, Diehl AM, Patel K, Syn WK.

Clin Sci (Lond). 2014 Jun;126(12):845-55. doi: 10.1042/CS20130473.

14.

An MAPK-dependent pathway induces epithelial-mesenchymal transition via Twist activation in human breast cancer cell lines.

Li NY, Weber CE, Wai PY, Cuevas BD, Zhang J, Kuo PC, Mi Z.

Surgery. 2013 Aug;154(2):404-10. doi: 10.1016/j.surg.2013.05.012.

PMID:
23889968
15.

Osteopontin up-regulates critical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype.

Li NY, Weber CE, Mi Z, Wai PY, Cuevas BD, Kuo PC.

J Am Coll Surg. 2013 Jul;217(1):17-26; discussion 26. doi: 10.1016/j.jamcollsurg.2013.02.025. Epub 2013 Apr 23. Erratum in: J Am Coll Surg. 2015 Aug;221(2):642.

PMID:
23619316
16.
17.

NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease.

Syn WK, Agboola KM, Swiderska M, Michelotti GA, Liaskou E, Pang H, Xie G, Philips G, Chan IS, Karaca GF, Pereira Tde A, Chen Y, Mi Z, Kuo PC, Choi SS, Guy CD, Abdelmalek MF, Diehl AM.

Gut. 2012 Sep;61(9):1323-9. doi: 10.1136/gutjnl-2011-301857. Epub 2012 Mar 17.

18.

Osteopontin regulates epithelial mesenchymal transition-associated growth of hepatocellular cancer in a mouse xenograft model.

Bhattacharya SD, Mi Z, Kim VM, Guo H, Talbot LJ, Kuo PC.

Ann Surg. 2012 Feb;255(2):319-25. doi: 10.1097/SLA.0b013e31823e3a1c.

19.

Pharmacokinetic characterization of an RNA aptamer against osteopontin and demonstration of in vivo efficacy in reversing growth of human breast cancer cells.

Talbot LJ, Mi Z, Bhattacharya SD, Kim V, Guo H, Kuo PC.

Surgery. 2011 Aug;150(2):224-30. doi: 10.1016/j.surg.2011.05.015.

20.

Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis.

Mi Z, Bhattacharya SD, Kim VM, Guo H, Talbot LJ, Kuo PC.

Carcinogenesis. 2011 Apr;32(4):477-87. doi: 10.1093/carcin/bgr009. Epub 2011 Jan 20.

Supplemental Content

Loading ...
Support Center